Market Intelligence, Clinical Progress, and High-Purity Reagents for Hippo Pathway-Targeted Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TEAD3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TEAD3 Recombinant Protein (Full-Length & DBD) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed. |
View TEAD3 Products |
| Mutant Panel | TEAD3 Palmitoylation Site Mutants (C358S/C359S/C367S) and rs35080860 variant Theoretical MW verified. For inhibitor resistance and mutation mechanism studies. |
View TEAD3 Products |
| Gene Delivery | TEAD3 Premade Lentivirus Particles (ORF) For stable nuclear expression and reporter cell line construction. |
View TEAD3 Products |
| Benchmark Inhibitor Control | Anti-TEAD3 / Pan-TEAD Small Molecule Reference Biochemical positive control for assay validation. |
View TEAD3 Products |
| Validator | TEAD3 siRNA Set (3 unique targets) For knockdown verification and specificity controls. |
View TEAD3 Products |
| Paralog Control | TEAD1 Recombinant Protein For selectivity screening vs TEAD family members. |
View TEAD1 Products |
| Paralog Control | TEAD4 Recombinant Protein For selectivity screening vs TEAD family members. |
View TEAD4 Products |
| Pathway Partner | YAP1 Recombinant Protein Co-activator interaction partner for PPI assays. |
View YAP1 Products |
| Competitive Binder | VGLL4 Protein / Peptide Endogenous TEAD inhibitor for competition assays. |
View VGLL4 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity Screening (TEAD1/2/4 cross-reactivity) | TEAD Family Protein Panel (TEAD1/3/4) available with >95% purity, Sequence Verified by Mass Spec. Full TEAD1-4 panel for complete ortholog screening. |
| Palmitoylation Site Validation (Cys-targeted inhibitor resistance) | Site-Directed Mutant Proteins (C358S/C359S/C367S) and rs35080860 variant with confirmed theoretical MW. |
| YAP/TAZ Interaction Interface Mapping | Full-Length and Truncated Variants (DBD-only, N-terminal deletions) for domain mapping. Soluble, native-folded recombinant domains. |
| Biophysical Assay Stability (SPR/TSA) | Sequence Verified tags optimized for sensor chip immobilization. Endotoxin controlled (<1EU/µg). |
| Nuclear Localization & Stability | Lentivirus-Transduced Stable Cell Lines with Native Folding (HEK293T packaging). |
| False Positive Elimination | Sequence-Verified siRNA Controls for target-specificity confirmation. |
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the Hippo pathway has shifted upstream from YAP/TAZ to their obligate DNA-binding partners, the TEAD family transcription factors. While early development focused on pan-TEAD inhibitors (targeting TEAD1/4 predominantly), the field is recognizing distinct expression patterns and functional roles for TEAD3 in specific malignancies, including NF2-mutant schwannomas and select solid tumors.
Current clinical candidates (VT3989, IK-595, IAG933) primarily target the palmitoylation pocket conserved across all four TEAD paralogs. However, the next wave of R&D is exploring paralog-selective inhibitors to minimize compensatory mechanisms (TEAD1/4 upregulation upon TEAD2/3 inhibition) and tissue-specific toxicities. The emergence of TEAD3-specific PROTACs and allosteric inhibitors is anticipated within the 2025-2028 window. Furthermore, YAP/TEAD inhibition is increasingly recognized as a critical mechanism to overcome resistance to targeted therapies (such as KRAS and EGFR inhibitors) in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-TEAD Small Molecule (Palmitoylation inhibitors) | Vivace Therapeutics, Ikena Oncology, Roche, Mitobridge/Astellas | NF2-mutant Mesothelioma, NSCLC, Solid tumors | Paralog Selectivity Panel (TEAD1/3/4 with distinct C-terminal tails) and selectivity assay (high-purity TEAD1-4 panel) |
| Peptide/Miniprotein Inhibitors (YAP interface blockers) | Fudan Univ., Dana-Farber, Stanford, Kyowa Kirin, SpringWorks | Neurofibromatosis, Glioblastoma, Hippo-altered Cancers | YAP1-TEAD3 PPI Disruption Assay (Full-length recombinant YAP1/TEAD3, FRET/FP compatible) |
| Protein Degrader (PROTAC/Molecular Glues) | Novartis, Arvinas, Emerging biotechs | Solid Tumors (Targeted therapy resistant), Refractory cancers | Ternary Complex Formation (Need native TEAD3 & YAP1); Cell-Based Degradation Assays (Lentivirus-stable lines required) |
| Pan-TEAD siRNA / RNAi | Alnylam, Arrowhead (exploratory) | Hepatocellular carcinoma | Knockdown Validation Controls (Species-matched siRNA) |
Live TEAD3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: